Page 7 - Generation Bio News Today

Shares of Generation Bio Co. (NASDAQ:GBIO – Get Rating) have been given an average rating of “Moderate Buy” by the six research firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average […]

Generation Bio Co. (NASDAQ:GBIO – Get Rating) COO Antoinette Paone sold 2,914 shares of the business’s stock in a transaction dated Tuesday, April 25th. The shares were sold at an average price of $4.61, for a total value of $13,433.54. The sale was disclosed in a filing with the SEC, which is accessible through the […]

The growing demand for novel drugs, which hold potential for the treatment of previously untreatable intracellular targets has resulted in an adjacent and urgent need for efficient delivery

CAMBRIDGE, Mass., April 11, 2023 -- Generation Bio Co. , a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough,... | April 11, 2023

CAMBRIDGE, Mass., April 05, 2023 -- Generation Bio Co. , a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Yalonda Howze, J.D.... | April 5, 2023

Generation Bio Co. (NASDAQ:GBIO – Get Rating) saw a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 1,430,000 shares, an increase of 10.0% from the February 28th total of 1,300,000 shares. Based on an average daily trading volume, of 458,900 shares, the short-interest ratio […]

Generation Bio Co. (NASDAQ:GBIO – Get Rating) – William Blair issued their Q1 2023 EPS estimates for shares of Generation Bio in a report issued on Wednesday, March 22nd. William Blair analyst M. Minter anticipates that the company will post earnings per share of ($0.60) for the quarter. William Blair currently has a “Market Perform” […]

Needham & Company LLC reiterated their buy rating on shares of Generation Bio (NASDAQ:GBIO – Get Rating) in a research note published on Thursday morning, Benzinga reports. The brokerage currently has a $14.00 price target on the stock. Separately, JMP Securities lowered their price objective on Generation Bio from $7.00 to $2.23 and set a […]

Needham & Company LLC reiterated their buy rating on shares of Generation Bio (NASDAQ:GBIO – Get Rating) in a report published on Thursday, Benzinga reports. The brokerage currently has a $14.00 price target on the stock. Separately, JMP Securities decreased their price target on shares of Generation Bio from $7.00 to $2.23 and set a […]

In a late stage trial Dupixent, jointly developed with Regeneron, led to a 30% reduction in moderate or severe acute exacerbations of chronic obstructive pulmonary disease (COPD), a potentially deadly disease marked by progressive lung function decline. Masimo CEO waives right to $600 million payout in fight with activist investor Masimo Corp Chief Executive Joe Kiani has waived his rights for roughly $600 million in special payment if the U.S. medical device maker appoints a lead independent ...